(Research Article)

10

IJPSR (2014), Volume 5, Issue 9



INTERNATIONAL JOURNAL

Received on 24 February 2014; received in revised form, 19 April 2014; accepted, 30 May 2014; published 01 September 2014

STUDYING THE ACCELERATED PHOTOSTABILITY OF CIPROFLOXACIN AND LOMEFLOXACIN IN TABLETS AND EYE DROPS

Mohammad Amer Al-Mardini and Zaynab Mando^{*}

Faculty of Pharmacy, Damascus University, P.O. Box 16531 Damascus, Syria.

Keywords:

Fluoroquinolones, Ciprofloxacin, Lomefloxacin, Photostability, Stability-indicating methods

Correspondence to Author: Zaynab Mando

Faculty of Pharmacy, Damascus University, P.O. Box 16531 Damascus, Syria.

E-mail: zeinmand@hotmail.com

ABSTRACT: The photostability of two fluoroquinolones: ciprofloxacin and lomefloxacin have been detected in tablets, and eye drops formulations using light-stability cabinet. Ciprofloxacin and lomefloxacin were subjected to stress conditions. The degradation products were well separated from the peak of the active substance. The stability of these compounds has been studied both in containers and under direct light in the light-stability cabinet. Samples were assayed immediately and at 1, 3, 6 months by stabilityindicating high-performance liquid chromatography methods with a photodiode array detector. The determination was performed on C18 (250 \times 4.6 mm, 5 μ m). The first mobile phase consisted of 0.025M phosphoric acid, and acetonitrile (87:13) pumped at a flow rate 2ml/min for ciprofloxacin, while the second consisted of water, acetonitrile, triethylamine (80:20:0.3) pumped at a flow rate 1ml/min for lomefloxacin. The UV detector was operated at 278 nm for ciprofloxacin and 288 nm for lomefloxacin. The methods were suitably validated for linearity, accuracy, precision, robustness, and selectivity. All validation parameters were within the acceptance range. Data analysis revealed that plastic and amber containers could not protect either ciprofloxacin or lomefloxacin in eye drops formulation from photodegradation after one month in the cabinet. White blister protects the two agents in tablets formulation after six months in the cabinet.

INTRODUCTION: The fluoroquinolones represent a relatively new class of antibiotics with outstanding therapeutic potential, attributable to their broad spectrum of antimicrobial activity and useful pharmacokinetic properties: they are orally active, their lipophilicity and low degree of plasma protein binding allow for excellent tissue penetration and concentrations ¹. Since quinolones discovery in the early 1960s, the quinolone group of antibacterials has generated considerable clinical and scientific interest ².



It has been estimated that over 10000 analogs of naldixic acid have been synthesized ³. The quinolone pharmacore is represented in **Fig. 1**³.



FIG. 1: THE QUINOLONE PHRMACORE

Quinolone phototoxicity is related to the generation of reactive oxygen species, including hydrogen peroxide, since these species cause severe tissue damage ⁴. These reactive oxygen species attack cellular lipid membranes, which results in lipid peroxidation and subsequent inflammation ⁵. Only a few studies on the photostability of fluoroquinolones have been published ^{6, 7}, and there were no studies on the effect of the packaging on the photostability of pharmaceutical preparations. Therefore, in this study an attempt has been made to determine the effect of light on the stability of ciprofloxacin, the most widely used agent in this class due to its broad spectrum and excellent oral bioavailability ⁸ and lomefloxacin, the most phototoxicity ⁵, after both direct exposure and in containers in the light-stability cabinet, using stability-indicating HPLC methods.

MATERIALS AND METHODS: Ciprofloxacin and Lomefloxacin working standards were obtained from the quality control and researches laboratories in the ministry of health- Syria. Tablets and eye drops were obtained from different local manufactures.

Acetonitrile and water of HPLC, phosphoric acid, hydrochloric acid, sodium hydroxide, and hydrogen peroxide were purchased from MERCK, triethylamine from PANREAC.

A Hitachi HPLC system equipped with an L-2130 isocratic and gradient pump, L-2200 auto-injector, L-2450 photodiode array detecto, and Knauer C18 column (250×4.6 mm, 5µm) were used.

The first mobile phase consisted of 0.025M phosphoric acid and acetonitrile (87:13, v/v)⁹ pumped at a flow rate 2ml/min for ciprofloxacin, while the second consisted of water, acetonitrile, triethylamine (80:20:0.3, v/v/v) pumped at a flow rate 1ml/min for lomefloxacin¹⁰. The UV detector was operated at 278 nm for ciprofloxacin and 288 nm for lomefloxacin.

Preparation of stock and standard solutions: Stock solution of ciprofloxacin 1 mg/ml was prepared in the mobile phase and diluted further with mobile phase to obtain the standard solution of $300 \ \mu\text{g/ml}$.

The stock solution of lomefloxacin 0.1 mg/ml was prepared in the mobile phase and diluted further with mobile phase to obtain the standard solution of 60μ g/ml.

Assay methods: Assay methods of ciprofloxacin and lomefloxacin are shown in Table 1.

 TABLE 1: ASSAY METHODS OF CIPROFLOXACIN

 AND LOMEFLOXACIN

Light	Heat	H_2O_2	NaOH	HCl	
50%	0%	5%	39%	23%	Degradation
					percentage
7.61	-	5.2	8.8	14.62	Resolution
					factor

Method validation: Method validation procedure was based on the recommendations of the international conference on harmonization Q2 (R1) for analytical procedures validation ¹¹

Stability- Indicating Study: ¹² The stability study consists of the following challenges: exposure to hydrogen peroxide, acid and alkali hydrolysis, and exposure to heat and light.

A standard solution at 10 times the normal working concentration was prepared. 10 ml aliquots of the sample were taken into five separate 100 ml volumetric flasks and treated as follows:

20 ml of 5N HCl was added and immersed in a boiling water bath for one hour.

20 ml of 5N NaOH was added and immersed in a boiling water bath for one hour.

10 ml of H_2O_2 20% was added and let stand 30 minutes.

Stored at 60°C for one week. Stored under white light for one week.

Each sample was diluted to the mark with RO/DI water. The acid sample was neutralized with 20 ml 5N NaOH before dilution and the alkali sample with 20 ml 5N HCl before dilution.

Stability Study: First, samples of pharmaceutical preparations (tablets and eye drops) for each of ciprofloxacin and lomefloxacin have been assayed (time zero).

After that, other samples have been incubated in a light-stability cabinet designed for light-stability tests in compatible with the second option for light sources identified in the international conference on harmonization topic Q1B for the photostability testing ¹³, so that is maintained at a temperature 25 °C and a relative humidity of 40% during the study period, amounting to six months.

Part of the samples was incubated under direct exposure to light (direct light), another part was incubated within its direct package (white blister, amber, and plastic containers), while the rest of the samples were incubated after suitable protection from light (dark). The changes in the incubated samples have been recorded and studied according to the assay of the active ingredient using validated methods. The results were compared to determine the effect of the light on the stability of the active substances in their dosage forms during storage and consumption, and the effect of the packaging containers on the protection from light.

Statistical Studies:

Fisher Test: Fisher test was used to compare variances between assay results of the active ingredients in each group of samples at 95% confidence limits.

Student Test: Student test was performed for comparison between the average weights of the active ingredients in each of the conditions used (light, dark, white blister, plastic, and amber containers) at 95% confidence limits.

RESULTS AND DISCUSSION:

Verifying for the Assay Methods Stability-Indicating: The assay methods of ciprofloxacin and lomefloxacin were verified for their stabilityindicating as the hardest conditions were applied to accelerate the degradation of the active ingredients. The methods proved to be suitable for the use in the stability study of ciprofloxacin and lomefloxacin. They were able to differentiate selectively between the active substance and its degradation products, as the resolution factor was more than 1.5 in all mediums (**Tables 2 & 3, Fig. 2 - 9**).

TABLE 2: LOMEFLOXACIN UNDER STRESS CONDITIONS
--

Light	Heat	H_2O_2	NaOH	HCl	
56%	0%	21.5%	47.5%	46%	Degradation
					percentage
9.31	-	9.42	9.54	2.91	Resolution
					factor

Assay methods of ciprofloxacin								
30°C	Column temperature							
0.025M phosphoric acid and	Mobile phase							
acetonitrile (87:13). The PH								
was adjusted to 3 using								
triethylamine 9								
2 ml/min	Flow rate							
278 nm	Wavelength							
300 µg/ml	Standard concentration							
Assay methods of	i lomefloxacin							
24°C	Column temperature							
Water, acetonitrile,	Mobile phase							
triethylamine (80:20:0.3). The								
PH was adjusted to 3.3 using								
phosphoric acid ¹⁰ .								
1 ml/min	Flow rate							
288 nm	Wavelength							
60 µg/ml	Standard concentration							



International Journal of Pharmaceutical Sciences and Research



The methods also showed the stability of both compounds at high temperatures where there has been no damage after incubation at a temperature of 60 °C for a week as it appears in the Fig. 10 and



11 as well as their sensitivity against the light, which turned out through the significant contraction in their concentrations after exposure to white light for one week, as shown in Fig. 12 & 13.

necessitated a gradually increased until 5N

concentration where we got a suitable degradation.



For acid and alkaline mediums, no damages were noticed when using 0.5 N concentrations of hydrochloric acid and sodium hydroxide, which has

International Journal of Pharmaceutical Sciences and Research

3649

Validation of the Assay Methods: The assay method of lomefloxacin was validated, and all the parameters met the recommendations of ICH for analytical method validation **Table 4**.

The linear equation and correlation coefficient were: Y=3163697X+359440, 0.9994, respectively **Fig. 14**. This demonstrates the linearity of this method and its suitability for the analysis of lomefloxacin.



FIG. 14: RELATION BETWEEN CONCENTRATION AND PEAK AREA OF LOMEFLOXACIN

The results of accuracy showed that the method is accurate, with an average percentage recovery 102.18.

The relative standard deviation for repeatability was 0.71, and for intermediate precision was 1.17.

The purity of analyte peak and the RSD value of < 2% (0.22) indicate that the method is selective for analysis of lomefloxacin in its dosage forms.

The results of the robustness test indicate that the method is robust. The percentage recovery for the assay values (n=5) were 98.72, 100.24, 99.32. The relative retention time of samples was 0.998, 0.997, and 0.997.

The assay method of ciprofloxacin was validated, and all the parameters met the recommendations of ICH for analytical method validation **Table 4**.

The linear equation and correlation coefficient were: Y=1652531X-4109032, 0.9983, respectively **Fig. 15**. This demonstrates the linearity of this method and its suitability for the analysis of ciprofloxacin.



FIG. 15: RELATION BETWEEN CONCENTRATION AND PEAK AREA OF CIPROFLOXACIN

The results of accuracy showed that the method is accurate, with an average percentage recovery 101.68. The relative standard deviation for repeatability was 1.19, and for intermediate precision was 0.78.

The purity of analyte peak and the RSD value of < 2% (0.18) indicate that the method is selective for analysis of lomefloxacin in its dosage forms.

The results of the robustness test indicate that the method is robust. The percentage recovery for the assay values (n=5) were 97.71, 100.39, 97.72. The relative retention time of samples was 0.998, 1, and 0.996.

TABLE 4: VALIDATION RESULTS OF THE HPLC METHOD OF LOMEFLOXACIN & CIPROFLOXACIN										
	Retention	Linearity	Accuracy	Precision		Selectivity	Robustness			
	time		Mean	RSD%		RSD%	Mean Recovery% / RRT			
			Recovery%							
Lome-	7.7 min.	\mathbf{R}^2	102.18	Intermediate	Repeatability	0.22	1.1	1 ml/min	0.9	
floxacin		=0.9994		precision						
				1.17	0.71		99.32	100.24	98.72	
							0.997	0.997	0.998	
Cipro-	12.2 min.	\mathbf{R}^2	101.68	0.78	1.19	0.18	1.9	2 ml/min	2.1	
floxacin		=0.9983					97.71	100.39	97.72	
							0.996	1	0.998	

Stability Studies on Dosage Forms: When exposing the tablets (Ciprofloxacin and Lomefloxacin) directly to light within the light-stability cabinet, there was no decrease in the

concentration of the active substances after 3 months, in other words, the difference between concentrations of the active ingredients in the dark and the light was not statistically significant. At the

International Journal of Pharmaceutical Sciences and Research

end of the exposure period after 6 months, the decrease in the concentrations of the active substances was substantially and statistically significant (around 1.5%, 4.5%, respectively), as a result of photodegradation and not return to the forces of luck and coincidence or analytical errors.

No decrease was noticed in the concentration of the active ingredients when the tablets exposed to light within the white blister even after 6 months in the cabinet, and the differences were insignificant **Table 5**.

TABLE 5: COMPARING STATISTICAL RESULTS IN TABLETS AFTER LIGHT EXPOSURE

	Ciprofloxa	cin		Lomefloxacin					
	Time1 month3 months6 months				Time	1 month	3 months	6 months	
	zero					zero			
Dark	99.89	98.85	98.12	98.65	Dark	103.18	103.3	99.73	99.15
Direct light	99.89	98.13	98.06	97.11	Direct light	103.18	102.85	99.64	94.93
Difference	-	insignificant	insignificant	Significant	Difference	-	insignificant	Insignificant	Significant
Dark	100.87	101.43	100.94	101.15	Dark	99.78	98.72	97.94	94.83
Blister	100.87	100.98	101.03	100.64	Blister	99.78	98.84	97.93	95.03
Difference	-	insignificant	insignificant	Insignificant	Difference	-	insignificant	Insignificant	Insignificant

For the eye drops, the degradation was clear since the first month of the direct exposure to light (about 30% .84%, respectively), as well as when exposing the drop to light within both the amber and plastic containers, where the decrease in the concentration of the active substances was substantially and statistically significant after one month (about 2% in both containers for ciprofloxacin, 1.5% in the amber container respectively), as well as when exposing the drop to light within both the amber and plastic containers, where the decrease in the concentration of the active substances was substantially and statistically significant after one month (about 2% in both containers for ciprofloxacin, 1.5% in the amber container and 9% in the plastic container for Lomefloxacin) as a result of photodegradation **Table 6**.

Average of concentrat						Lomefloxacin			
	Time 1 month 3 months 6 months					Time	1 month	3 months	6 months
	zero					zero			
Dark	102.54	101.03	100.86	100.63	Dark	101.57	99.22	98.83	96.34
Direct light	102.54	70.83	51.56	10.33	Direct light	101.57	14.85	4.42	1.45
Difference	-	significant	significant	Significant	Difference	-	significant	significant	Significant
Dark	101.2	100.3	100.01	100.15	Dark	100.94	99.33	99.14	100
Amber	101.2	98.33	93.35	88.11	Amber	100.94	97.93	96.31	90.09
Plastic	101.2	97.96	92.63	91.16	Plastic	100.94	90.26	85.83	82.82
Difference	-	significant	significant	Significant	Difference	-	significant	significant	Significant

CONCLUSION: А reverse phase highperformance liquid chromatography methods have been used for the determination of ciprofloxacin and lomefloxacin in tablets and eye drops dosage forms. The methods were suitably validated and studied for their stability-indicating. The degradation products were well separated from the peak of the active substance. The results of the stability study indicate that white blister can protect tablets from degradation induced by light. They also show that transparent containers should be avoided in eye drops formulations, instead of amber or plastic containers can be used, with an emphasis on the need to keep the eye drops within

the outer package and not only within the inner package.

ACKNOWLEDGEMENT: Many thanks for the co-workers in Al-Fares factory for pharmaceutical industries-Syria for their help and support.

CONFLICT OF INTEREST: Nil

REFERENCES:

- 1. Fitton A: The Quinolones. An overview of their pharmacology. Clinical Pharmacokinetics 1992; 22: 1-11.
- 2. Emami S, Shafiee A and Foroumadi A: Quinolones: Recent Structural and Clinical Developments. Iranian Journal of Pharmaceutical Research 2005; 3: 123-36.

- 3. Tillotson GS: Quinolones: structure-activity relationships and future predictions. Journal of Medical Microbiology 1996; 44: 320-24.
- 4. De Sarro A and De Sarro G: Adverse Reactions of Fluoroquinolones. An Overview on Mechanistic Aspects. Current Medicinal Chemistry 2001; 8: 371-84.
- 5. Fish DN: Fluoroquinolone Adverse Effects and Drug Interactions: Specific Adverse Effects. Pharmacotherapy 2001; 21: 253-72.
- 6. Torniainen K, Tammilehto S and Ulvi V: The effect of pH, buffer type and drug concentration on the photodegradation of ciprofloxacin. International Journal of Pharmaceutics 1996; 132: 53-61.
- De Vries H and Beijersbergen van Henegouwen GMJ: Photochemical decomposition of Lomefloxacin *in-vitro* and *in-vivo*. Journal of Photochemistry and Photobiology B: Biology 2000; 58: 6-12.

- 8. Andriole V: The Quinolones. Academic Press. Third Edition 2000: 33-98.
- 9. United States Pharmacopoeia (USP35-2012)
- 10. Santoro M, Kassab N and Singh A: Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolone antibiotics in pharmaceutical preparations by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 2006; 40: 179-84.
- International Conference on Harmonization Q2 (R1). Validation of Analytical procedures: Text and Methodology. Finalised Guideline November 1996.
- 12. Nilsen C: Managing the Analytical Laboratory. Interpharm Press, Inc 1996.
- International Conference on Harmonaization Topic Q1B. Photostability Testing of New Active Substances and Medicinal Products. Finalized Guideline November 1996.

How to cite this article:

Al-Mardini MA and Mando Z: Studying the accelerated photostability of ciprofloxacin and lomefloxacin in tablets and eye drops. Int J Pharm Sci & Res 2014; 5(9): 3646-52. doi: 10.13040/IJPSR.0975-8232.5(9).3646-52.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to ANDROID OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)